Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are long-chain polyunsaturated fatty acids (PUFAs) derived from marine sources. In the context of research at The University of Texas Health Science Center at San Antonio, these fatty acids are being investigated in Phase 0 clinical trials for their chemopreventive potential in breast cancer, particularly among obese post-menopausal survivors. The mechanism of action involves the competitive inhibition of cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, which reduces the conversion of arachidonic acid into pro-inflammatory eicosanoids such as prostaglandin E2 (PGE2). By modulating these inflammatory pathways and altering the eicosanoid profile, omega-3 fatty acids may mitigate the obesity-driven inflammation that promotes tumor progression and recurrence. These studies often evaluate omega-3 fatty acids as an adjunctive therapy alongside other agents like aspirin to achieve synergistic inhibition of the COX-2 pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omega-3 fatty acids (UT Health San Antonio).